Allogene Therapeutics (ALLO) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
ProKidney is the larger company by market cap ($626.7 million vs $494.1 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ALLO | PROK |
|---|---|---|
| Share price | $1.43 | $1.57 |
| Market cap | $494.05M | $626.72M |
| 1-day change | -2.05% | -1.87% |
| EPS (TTM) | $-0.66 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $3.48 |
| 52-week low | $1.04 | $1.30 |
| Distance from 52-week high | -67.94% | -54.89% |
| Average volume | 5.78M | 1.31M |
| Shares outstanding | 345.49M | 208.93M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ALLO vs PROK FAQ
Which is bigger, Allogene Therapeutics or ProKidney?
ProKidney (PROK) is larger, with a market capitalization of $626.72M compared with $494.05M for Allogene Therapeutics (ALLO).
Are Allogene Therapeutics and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.